Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus

https://www.techtransfer.nih.gov/tech/tab-4865?utm_campaign=+64739365&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= In December 2019, the U.S. Food and Drug Administration approved ERVEBO for use as a vaccine against Ebola virus disease, caused by the Zaire ebolavirus species. However, this vaccine is not effective against disease caused by the Sudan ebolavirus (SUDV) species, due to significant variations in structure between the two species. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a vaccine candidate for SUDV with a vesicular stomatitis virus (VSV) backbone similar to that used for ERVEBO. The new candidate has shown promise in efficacy studies conducted in nonhuman primates. The VSV platform also has the potential to enhance the safety of the vaccine while inducing a strong, rapid immune response. To learn more about this collaboration opportunity, visit https://www.techtransfer.nih.gov/tech/tab-4865 or contact Terrence Joyce at terrence.joyce@nih.gov and reference E-002-2023. #Ebola #NIAID #NIAIDTechTransfer